Functional Selectivity of Muscarinic Receptor Antagonists for Inhibition of M3-Mediated Phosphoinositide Responses in Guinea Pig Urinary Bladder and Submandibular Salivary Gland
- 1 September 2004
- journal article
- Published by Elsevier in The Journal of Pharmacology and Experimental Therapeutics
- Vol. 310 (3) , 1255-1265
- https://doi.org/10.1124/jpet.104.067140
Abstract
Binding and functional affinities of the muscarinic acetylcholine (mACh) receptor antagonists darifenacin, tolterodine, oxybutynin, and atropine were assessed in Chinese hamster ovary (CHO) cells expressing the human recombinant M2 (CHO-m2) or M3 (CHO-m3) receptors, and in guinea pig bladder and submandibular gland. In [N-methyl-3H]scopolamine methyl chloride binding studies in CHO cells, darifenacin displayed selectivity (14.8-fold) for the M3 versus M2 mACh receptor subtype. Oxybutynin was nonselective, whereas atropine and tolterodine were weakly M2-selective (5.1- and 6.6-fold, respectively). Antagonist functional affinity estimates were determined by the inhibition of agonist-induced [3H]inositol phosphate accumulation in CHO-m3 cells and antagonism of the agonist-induced inhibition of forskolin-stimulated cyclic AMP accumulation in CHO-m2 cells. Darifenacin was the most M3-selective antagonist (32.4-fold), whereas oxybutynin, atropine, and tolterodine exhibited lesser selectivity. Functional affinity estimates in guinea pig urinary bladder and submandibular salivary gland using indices of phosphoinositide turnover revealed that oxybutynin, darifenacin, and tolterodine each displayed selectivity for the response in the bladder, relative to that seen in the submandibular gland (9.3-, 7.9-, and 7.4-fold, respectively). In contrast, atropine displayed a similar affinity in both tissues. These data demonstrate that in bladder, compared with submandibular gland from a single species, the mACh receptor antagonists darifenacin, tolterodine, and oxybutynin display selectivity to inhibit agonist-mediated phosphoinositide responses. It is proposed that both responses are mediated via M3 mACh receptor activation and that differential functional affinities displayed by some, but not all, antagonists are indicative of the influence of cell background upon the pharmacology of the M3 mACh receptor.Keywords
This publication has 36 references indexed in Scilit:
- Predicting therapeutic value in the lead optimization phase of drug discoveryNature Reviews Drug Discovery, 2003
- Blockade of body weight gain and plasma corticosterone levels in Zucker fatty rats using an orally active neuropeptide Y Y1 antagonistBritish Journal of Pharmacology, 2002
- The minor population of M3‐receptors mediate contraction of human detrusor muscle in vitroJournal of Autonomic Pharmacology, 2001
- The overactive bladderBJU International, 2001
- Functional characterization of rat submaxillary gland muscarinic receptors using microphysiometryBritish Journal of Pharmacology, 2001
- Muscarinic receptor subtype selective toxinsLife Sciences, 1997
- Depressant effects of hypoxia and hypoglycaemia on neuro‐effector transmission of guinea‐pig intestine studied in vitro with a pharmacological modelBritish Journal of Pharmacology, 1997
- Expression of Muscarinic M sub 3 -Receptors Coupled to Inositol Phospholipid Hydrolysis in Human Detrusor Cultured Smooth Muscle CellsJournal of Urology, 1995
- The Cheng-Prusoff relationship: something lost in the translationTrends in Pharmacological Sciences, 1993
- Muscarinic M3 receptors are coupled to two signal transduction pathways in rat submandibular cellsEuropean Journal of Pharmacology: Molecular Pharmacology, 1990